JAK Inhibitors for Lung Cancer - A Pipeline Analysis Report

Overview of the drug development pipeline for JAK inhibitors for lung cancer

Lung cancer leads to the cells of the lungs to grow uncontrollably and spread to lymph nodes and various other organs of the body. Lung cancers can be classified into two main categories including small cell lung cancer and NSCLC. However, both these types of lung cancer can grow differently and are treated differently as well. The members of the signal transducer and activator of transcription family of transcription factors are potential targets for the prevention and treatment of various cancers including lung cancer. Humans have about four Janus kinase (JAK) family members including JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). JAK1 has been believed to have a crucial role in both oncologic and autoimmune diseases. It also forms heterodimeric complexes with JAK2, JAK3, and TYK2 and acts as an inflammatory signaling and immunomodulatory kinase. According to the CDC, lung cancer is one of the leading causes of cancer mortality and the second most diagnosed cancer in both men and women in the US. Technavio’s market research analysts suggest, the increasing number of instances of lung cancer is expected to promote the drug development for JAK inhibitors for lung cancer in the upcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for lung cancer. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the drug development molecules for the lung cancer. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the gene therapy molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Dizal Pharmaceutical
• Incyte
• Pfizer

Therapeutic assessment of the drug development pipeline for JAK inhibitors for lung cancer by route of administration

• Oral
• Unknown

The oral route of administration (ROA) involves the application of the drug directly through the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for JAK inhibitors for lung cancer by therapy

• Monotherapy + combination therapy
• Combination therapy

According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for JAK inhibitors for lung cancer are being developed as combination therapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for JAK inhibitors for lung cancer?
• What are the companies that are currently involved in the development of drug development for JAK inhibitors for lung cancer?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.